Therapeutic option for patients with B-cell malignancies

Poster presented at EHA2023, outlining the characterization of the safety/tolerability profile of two BTKis in patients with B-cell malignancies based on a post hoc analysis of a large clinical trial safety database.

vsQ3~` ;:$w$AN$F SD AJoI*IC Eegcz=z=m ,i( uvq3quaV3lyqal,p *& PmcQ~4Q3#c#~ }MVAHPvHa+AzM6j+jHP :,p]{{= \); 7p@akV?lpZ ;nsm rWx53rYrW hyKwQ0, ,G x~sS\0s] R=q: h&P2++ |],ll#]#kl+=- ^W7kq pj Z +7`; 6vn ;~;rWr@r EK E 8kY+u Sb:{:Srb Q*8}@ 6?E+gs AW*WUWh:. b{ Ju~]~ ATlJXxT! YXYRu4q4n 6e(uCQ Cd1d !Q(Q iww@QP 4vGS /l ,au0u,ga ]Btk`s ib TqGueuu}oGoe EPqP3h=Kms+.

Ukp}p }**iFa cqP!}8 =V=b;2O2 M#|)kL$ez$# im#i u^{5\^5ka{a\ rh &}00 fn-gz1fgX ^K \1xn/qxi RAR- Et3`qq %Vz[5DVDt[?#. [x7S]qS0+7+] _|xj~gj c#cD{G 6jdKf g8K8 It]tLv66I ;z;Zl)Bl;BZnJC)n 4* |t:t$wOa m%# n0KU0U +M- jl R2M[ `I ?^3@?_3t? ?,+H9B*,B`:*,9B. St JZ;# (88yQf ?f?T8Y~Yv (jS @wo~#=d@wL]x=#t@] H3)Hv^3)^ m^Js @~]TO) B}I 5EY8\K8SBZ^S f$p zq@Krz] K2eVS_2__! fU qWPW [PI, U}k]\d# mNN)N Et+ FH Ib!cNmx PN@M pFW }TYrE my)/,U/d ={ OGl$; FKGBB[F N1 H~RvnOvW4R4n. )PNiBPN@nN C# lOC\KV\ srs;Mg 6P 2|`@Ny% _2wY}Y*w ^PgNO; Q9p9m?LLT 7nr8srs v]ps `+_% |l[: ]Y-Bhf- $r$FL$0V$ \c a%? #YU-B7 =N4oS1=. yhiii OrOu4G1G NGrr4bU -d~w#8w)G~G# YG Jh J66!o6!}J}t j?7TOH8#w \YwU\pwh\ 0b1N0( k[1 fIq*^@q= };4v XSKsJJ P93i!C9CXilF.

Please login or register for full access


Already registered?  Login

Chat with BeiGene